MedTrace Logo

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

NCT02399410 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-01-30

No results posted yet for this study

Summary

The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

perioperative chemotherapy plus bevacizumab

preoperative and postoperative combination chemotherapy with bevacizumab

PROCEDURE

cytoreductive surgery

complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.

DRUG

Intraperitoneal Oxaliplatin

Pump-driven intraperitoneal administration of oxaliplatin

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Wim P Ceelen, MD,PhD · University Hospital, Ghent

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-04
Primary Completion
2023-11-09
Completion
2023-11-09

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02399410 on ClinicalTrials.gov